微创外置心室辅助装置联合ECMO治疗难治性心源性休克
结果显示平均流量5.3±1.1 L/min,院内死亡率32%,68%患者过渡至下一步治疗,6个月和1年生存率分别为92%和77%,提示该策略可行。
要点
- 微创外置VAD联合ECMO可作为经皮短效MCS失败后的可行过渡策略
- 平均流量5.3±1.1 L/min,支持中位时间22天,出血和脑血管事件需警惕
- 68%患者存活至下一步治疗,包括心肌恢复、换持久VAD或心脏移植
核心结论
- 对经皮短效MCS难治的心源性休克患者,微创外置VAD策略可行。
研究设计与样本
- 所有患者均行小切口左室心尖插管和腋动脉插管建立外置磁悬浮离心泵VAD,均未使用体外循环。
- 17例(68%)因双心室衰竭或肺部并发症加用ECMO,将股静脉插管作为额外流入源接入VAD回路。
主要发现
- 患者平均年龄58±9.1岁,80%为男性,全部为INTERMACS profile I级难治性心源性休克。
- 平均流量5.3±1.1 L/min,外置VAD支持中位时间22天;ECMO中位支持4天后撤除。
- 主要并发症:出血事件7例(28%),脑血管事件4例(16%);院内死亡率32%。
- 17例(68%)存活至下一步治疗:心肌恢复3例(12%),更换持久VAD 12例(48%),心脏移植2例(8%);6个月和1年Kaplan-Meier生存率分别为92%和77%。
临床怎么用
- 对于经皮短效MCS支持仍难治的心源性休克患者,可考虑微创外置VAD作为过渡策略。
- 双心室衰竭或肺部并发症患者可加用ECMO,并将股静脉插管接入VAD回路。
- 支持期间需密切监测出血和脑血管事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The use of short-term mechanical circulatory support (MCS) has increased in the treatment of refractory cardiogenic shock (RCS). Percutaneous short-term MCS technology has emerged rapidly; however, limitations in flow and durability remain. We therefore investigated a minimally invasive surgical approach using an external ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) in patients with RCS. METHODS: Twenty-five patients underwent minimally invasive external VAD insertion with a magnetically levitated centrifugal pump for various causes of cardiogenic shock between April 2010 and May 2016. An external VAD was established with left ventricular apical cannulation through a minithoracotomy and right or left axillary artery cannulation. In patients with biventricular failure or pulmonary complications, femoral venous cannulation was added as an additional inflow source, and ECMO was spliced into the external VAD circuit. RESULTS: Mean patient age was 58 ± 9.1 and 80% were men. All patients were in Interagency Registry for Mechanically Assisted Circulatory Support profile I RCS. The aetiology of RCS was decompensated chronic heart failure in 13 (52%), and acute myocardial infarction in 12 (48%). Twenty-three (92%) received percutaneous short-term MCS prior to surgery. The procedure was performed without cardiopulmonary bypass in all patients. ECMO was added in 17 patients (68%) and explanted after a median of 4 days of support. The average flow obtained was 5.3 ± 1.1 l/min. The median duration of external VAD support was 22 days. Major complications during support included bleeding events in seven (28%) and cerebrovascular events in four (16%). The in-hospital mortality rate was 32%. Seventeen patients (68%) survived to the next destination including myocardial recovery in three (12%), device exchange to a durable VAD in 12 (48%) and heart transplantation in two (8%). The Kaplan-Meier survival rates at 6 months and 1 year were 92% and 77%, respectively. CONCLUSIONS: Our minimally invasive surgical approach using an external VAD is a feasible strategy for patients with cardiogenic shock who are refractory to percutaneous short-term MCS support.
引用
- Takeda K, Garan AR, Topkara VK, et al. Novel minimally invasive surgical approach using an external ventricular assist device and extracorporeal membrane oxygenation in refractory cardiogenic shock. Eur J Cardiothorac Surg. 2017. PMID: 27818380. doi:10.1093/ejcts/ezw349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。